Kendall Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.73M | Buy |
61,555
+4,770
| +8% | +$278K | 0.77% | 30 |
|
|
2025
Q4 | $3.06M | Sell |
56,785
-2,697
| -5% | -$130K | 0.64% | 41 |
|
|
2025
Q3 | $2.68M | Buy |
59,482
+3,730
| +7% | +$174K | 0.6% | 46 |
|
|
2025
Q2 | $2.58M | Buy |
55,752
+8,210
| +17% | +$403K | 0.68% | 41 |
|
|
2025
Q1 | $2.9M | Sell |
47,542
-90
| -0.2% | -$5.25K | 0.85% | 34 |
|
|
2024
Q4 | $2.69M | Buy |
47,632
+2,985
| +7% | +$167K | 0.79% | 38 |
|
|
2024
Q3 | $2.31M | Sell |
44,647
-2,295
| -5% | -$108K | 0.71% | 42 |
|
|
2024
Q2 | $1.95M | Sell |
46,942
-1,542
| -3% | -$69K | 0.65% | 46 |
|
|
2024
Q1 | $2.63M | Buy |
48,484
+1,743
| +4% | +$88.8K | 0.9% | 26 |
|
|
2023
Q4 | $2.4M | Buy |
46,741
+610
| +1% | +$32K | 0.93% | 26 |
|
|
2023
Q3 | $2.68M | Buy |
46,131
+1,022
| +2% | +$62.6K | 1.19% | 17 |
|
|
2023
Q2 | $2.88M | Buy |
45,109
+275
| +0.6% | +$18.4K | 1.26% | 14 |
|
|
2023
Q1 | $3.11M | Buy |
44,834
+1,066
| +2% | +$75.2K | 1.49% | 14 |
|
|
2022
Q4 | $3.15M | Sell |
43,768
-1,771
| -4% | -$134K | 1.59% | 12 |
|
|
2022
Q3 | $3.24M | Buy |
45,539
+1,240
| +3% | +$90K | 1.88% | 9 |
|
|
2022
Q2 | $3.41M | Sell |
44,299
-430
| -1% | -$32.7K | 1.88% | 10 |
|
|
2022
Q1 | $3.27M | Buy |
44,729
+2,315
| +5% | +$155K | 1.58% | 14 |
|
|
2021
Q4 | $2.65M | Buy |
42,414
+3,472
| +9% | +$204K | 1.26% | 20 |
|
|
2021
Q3 | $2.3M | Buy |
38,942
+5,895
| +18% | +$388K | 1.25% | 22 |
|
|
2021
Q2 | $2.21M | Buy |
33,047
+2,780
| +9% | +$181K | 1.24% | 21 |
|
|
2021
Q1 | $1.91M | Buy |
30,267
+4,335
| +17% | +$270K | 1.18% | 25 |
|
|
2020
Q4 | $1.61M | Buy |
25,932
+2,320
| +10% | +$143K | 1.17% | 30 |
|
|
2020
Q3 | $1.42M | Buy |
23,612
+930
| +4% | +$56K | 1.24% | 27 |
|
|
2020
Q2 | $1.33M | Buy |
22,682
+5,782
| +34% | +$346K | 1.28% | 29 |
|
|
2020
Q1 | $942K | Sell |
16,900
-3,125
| -16% | -$191K | 1.07% | 33 |
|
|
2019
Q4 | $1.28M | Buy |
20,025
+2,170
| +12% | +$124K | 1.01% | 39 |
|
|
2019
Q3 | $905K | Buy |
17,855
+2,605
| +17% | +$122K | 0.8% | 48 |
|
|
2019
Q2 | $692K | Buy |
15,250
+2,285
| +18% | +$106K | 0.63% | 60 |
|
|
2019
Q1 | $619K | Buy |
12,965
+4,630
| +56% | +$231K | 0.59% | 60 |
|
|
2018
Q4 | $433K | Buy |
8,335
+2,535
| +44% | +$136K | 0.45% | 70 |
|
|
2018
Q3 | $360K | Buy |
+5,800
| New | +$344K | 0.31% | 83 |
|
Other funds holding BMY
VCM
VPM
Kendall Capital Management's BMY Position: Q1 2026 in Review
Kendall Capital Management increased its Bristol-Myers Squibb (BMY) stake by 8.4% in Q1 2026, buying an estimated $278K and bringing the position to 61,555 shares worth $3.73M. The position accounts for 0.77% of the portfolio, ranked #30.
Kendall Capital Management first reported a position in BMY in Q3 2018 and has held it in 31 quarters since. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Kendall Capital Management held 61,555 shares of Bristol-Myers Squibb worth $3.73M as of Q1 2026.
- Kendall Capital Management bought 4,770 Bristol-Myers Squibb shares in Q1 2026, an estimated $278K.
- Bristol-Myers Squibb made up 0.77% of Kendall Capital Management's portfolio in Q1 2026, its #30 holding.
- Kendall Capital Management first reported a position in Bristol-Myers Squibb in Q3 2018 and has held it in 31 quarters since.
- 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Kendall Capital Management's 13F filing for Q1 2026, filed 24 Apr 2026.